AIPRI Study – how to slow progression of non-diabetic nephropathy? Review article
Article Sidebar
Published:
Mar 31, 2009
Keywords:
benazepril, chronic glomerulonephritis, proteinuria, renal function
Main Article Content
Abstract
Pharmacological inhibition of the renin-angiotensin-aldosteron system (RAAS) constitutes a cornerstone strategy in the management of patients with chronic nephropathies with proteinuria and with chronic renal failure. In nondiabetic patients with chronic kidney disease, the benefits of RAAS intervention have been established in the AIPRI study, a randomized double-blind placebo-controlled trial comparing benazepril with placebo. After 3-yr follow-up, benazepril provides renoprotection by a significant proteinuria reduction and risk reduction in the treatment group for doubling baseline serum creatinine concentration or the need for dialysis.
Article Details
How to Cite
Małecki , R. (2009). AIPRI Study – how to slow progression of non-diabetic nephropathy?. Medycyna Faktow (J EBM), 2(1(2), 45-50. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2681
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Campbell R.C., Ruggenenti P., Remuzzi G.: Halting the progression of chronic nephropathy. J. Am. Soc. Nephrol. 2002; 13: 190-5.
2. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: P3-13.
3. Anderson S., Rennke H.G., Brenner B.W.: Therapeutic advantage of converting enzym inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
4. Lewis E.J., Hunsicker L.G., Bain R.P. et al.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993; 329: 1456-62.
5. Ruggenenti P., Fassi A., Ilieva A.P. et al. (for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators): Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004; 351: 1941-51.
6. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M., Ponticelli C., Ritz E., Zucchelli P.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
7. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
8. Ihle B.U. et al.: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am. J. Kidney Dis. 1996; 27: 489-495.
9. The GISEN Group: Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857-63.
10. Jafar T.H. et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001; 135(2): 73-87.
11. Giatras I., Lau J., Levey A.S.: Effect of angiotensin-converting-enzyme inhibitors on the progression of non-diabetic renal disease: A meta-analysis. Ann. Intern. Med. 1997; 127: 337-345.
12. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
13. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 2000; 160: 685-93.
14. Rutkowski P., Tylicki L., Renke L. et al.: Low dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260-268.
2. Wolf G., Butzmann U., Wenzel U.O.: The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron. Physiol. 2003; 93: P3-13.
3. Anderson S., Rennke H.G., Brenner B.W.: Therapeutic advantage of converting enzym inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 1986; 77: 1993-2000.
4. Lewis E.J., Hunsicker L.G., Bain R.P. et al.: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 1993; 329: 1456-62.
5. Ruggenenti P., Fassi A., Ilieva A.P. et al. (for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators): Preventing microalbuminuria in type 2 diabetes. N. Engl. J. Med. 2004; 351: 1941-51.
6. Maschio G., Alberti D., Janin G., Locatelli F., Mann J.F., Motolese M., Ponticelli C., Ritz E., Zucchelli P.: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N. Engl. J. Med. 1996; 334(15): 939-945.
7. Locatelli F., Del Vecchio L.: How long can dialysis be postponed by low protein diet and ACE inhibitors? Nephrol. Dial. Transplant. 1999; 14: 1360-1364.
8. Ihle B.U. et al.: Angiotensin-converting enzyme inhibition in nondiabetic progressive renal insufficiency: a controlled double-blind trial. Am. J. Kidney Dis. 1996; 27: 489-495.
9. The GISEN Group: Randomized placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857-63.
10. Jafar T.H. et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann. Intern. Med. 2001; 135(2): 73-87.
11. Giatras I., Lau J., Levey A.S.: Effect of angiotensin-converting-enzyme inhibitors on the progression of non-diabetic renal disease: A meta-analysis. Ann. Intern. Med. 1997; 127: 337-345.
12. Hebert L.A.: Optimizing ACE-inhibitor therapy for chronic kidney disease. N. Engl. J. Med. 2006; 354: 189-191.
13. Bakris G.L., Weir M.R.: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern? Arch. Intern. Med. 2000; 160: 685-93.
14. Rutkowski P., Tylicki L., Renke L. et al.: Low dual blockade of the renin-angiotensin system in patients with primary glomerulonephritis. Am. J. Kidney Dis. 2004; 43: 260-268.